Trump's Drug Pricing EO: Headline Risk vs. Industry Impact

Analysis of Trump's Drug Pricing Executive Order

• 💡 The executive order (EO) on drug pricing is viewed as having more headline risk than substantive policy change.
• 🎯 The core idea of the EO is to lower US drug prices by benchmarking them against prices in other developed nations, potentially raising overseas prices.
• ⚠️ However, the EO is unlikely to be enacted as is because many international drug contracts are government-based, and enacting such a policy in the US would likely require congressional action to change laws.

Policy Mechanisms and Legal Challenges

• ❓ The EO notably lacks a provision to use the IRA's price negotiation component and peg it to a Most Favored Nation (MFN) pricing model.
• ⚖️ As it stands, there is little policy within the EO to take effect, with a 30-day clock for reference pricing analysis.
• 🏛️ Any significant changes would likely face heavy legal challenges in the courts, and altering Medicare pricing is also legally complex.

Industry Fundamentals and Sentiment

• 📉 If MFN pricing were to be removed, industry sentiment would likely improve.
• 🚢 Tariffs have been a fluctuating concern, with recent improvements in US-China relations easing broader tariff sentiment.
• 🌱 The fundamental drivers of the pharmaceutical sector remain unchanged, suggesting the industry is still investable despite near-term headwinds.
• 🚀 Specific companies like Eli Lilly and the GLP-1 drug market are highlighted as areas of continued interest.